Nebula Research & Development LLC Acquires New Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Nebula Research & Development LLC acquired a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 18,560 shares of the company’s stock, valued at approximately $639,000.

A number of other institutional investors have also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its stake in Harmony Biosciences by 66.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the company’s stock valued at $17,205,000 after buying an additional 200,000 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Harmony Biosciences by 33.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,788 shares of the company’s stock valued at $681,000 after buying an additional 4,911 shares in the last quarter. Dark Forest Capital Management LP bought a new position in Harmony Biosciences in the fourth quarter valued at approximately $536,000. Hsbc Holdings PLC lifted its stake in Harmony Biosciences by 13.5% in the fourth quarter. Hsbc Holdings PLC now owns 20,401 shares of the company’s stock valued at $701,000 after buying an additional 2,424 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Harmony Biosciences by 29.3% in the fourth quarter. MetLife Investment Management LLC now owns 23,127 shares of the company’s stock valued at $796,000 after buying an additional 5,242 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on HRMY shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Mizuho boosted their price objective on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 18th. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Finally, UBS Group cut their price objective on shares of Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Monday. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Harmony Biosciences currently has a consensus rating of “Buy” and a consensus price target of $52.44.

Harmony Biosciences Price Performance

Shares of HRMY opened at $29.36 on Tuesday. The company has a market cap of $1.68 billion, a price-to-earnings ratio of 13.91, a PEG ratio of 0.47 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a 1-year low of $26.47 and a 1-year high of $41.61. The company’s fifty day simple moving average is $31.84 and its 200 day simple moving average is $34.23. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.11. The business had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.45 earnings per share. On average, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.